Circulating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may be risk factors for the development of colorectal cancer. On the other hand, IGF-II and IGFBP-2 are overexpressed in colorectal carcinomas. These contrasting backgrounds led us to investigate the relationship between serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma, in 345 volunteers attending a screening flexible sigmoidoscopy trial (entry criteria: healthy, aged 55-64 yr). The most striking finding was an elevated mean serum IGF-II in individuals with adenomas (n ϭ 52) compared with controls (mean difference, 139 ng/mL; 95% confidence intervals, 82, 196; P Ͻ 0.0001). Logistic regression adjusting for confounding factors confirmed the significant association between IGF-II and adenoma occurrence (P Ͻ 0.0001) and revealed an additional positive association with serum IGFBP-2 (P Ͻ 0.0001). However, there was no association found between either serum IGF-I and/or IGFBP-3 and the presence of adenomas. Additionally, in 31 individuals with adenomas in whom levels were determined pre-and postpolypectomy, there was a significant fall in mean IGF-II (P Ͻ 0.001) and IGFBP-2 (P Ͻ 0.001) after adenoma removal, but no difference in IGF-II and IGFBP-2 concentrations between repeated samples in 20 individuals without adenomas. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy. (J Clin Endocrinol Metab 85: 3402-3408, 2000) 
ation with serum IGFBP-2 (P Ͻ 0.0001). However, there was no association found between either serum IGF-I and/or IGFBP-3 and the presence of adenomas. Additionally, in 31 individuals with adenomas in whom levels were determined pre-and postpolypectomy, there was a significant fall in mean IGF-II (P Ͻ 0.001) and IGFBP-2 (P Ͻ 0.001) after adenoma removal, but no difference in IGF-II and IGFBP-2 concentrations between repeated samples in 20 individuals without adenomas. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy. I NSULIN-LIKE growth factor I (IGF-I) and IGF-II are mitogenic and antiapoptotic polypeptides that have properties both as systemic hormones and as local tissue growth factors. They are synthesized principally in the liver, but also in a variety of extrahepatic tissues. In the circulation, IGF-I and IGF-II are bound to six high affinity binding proteins (IGFBPs); the majority bind to the major binding protein, IGFBP-3, forming a 150-kDa ternary complex with acid-labile subunit (1) . IGF-I is GH dependent and decreases steadily with age in adults after puberty. In adults, IGF-II occurs in quantities 3-fold that of IGF-I, is minimally GH dependent, decreases modestly with age, and has a greater affinity (4-fold) than IGF-I for IGFBP-2 (1, 2). In turn, IGFBP-2 is the second most abundant IGFBP, is inversely related to GH status, and increases with age in adults (1, 2) . The binding proteins account for the day to day stability of circulating IGF-I and IGF-II and modulate their long term bioavailability.
Colorectal cancer is the second most common cause of cancer-related deaths in the western world. There is compelling evidence that the majority of cancers arise from adenomatous polyps, referred to as the adenoma-carcinoma sequence (3, 4) . Experimental evidence for a role of IGF-I in colorectal carcinogenesis derives from its ability to influence the proliferative behavior of normal colonic epithelium and colonic cancer cell lines (5, 6) . Further evidence is gleaned from the observation that acromegaly, an endocrine disorder characterized by sustained elevated levels of GH and IGF-I, is associated with a moderately increased risk of developing colonic cancer (7) . Across the general population, circulating levels of IGF-I vary widely, and three nested case-control studies have shown that upper normal range IGF-I values predict the subsequent development of prostate (8) , breast (9) , and colorectal cancer (10) . In these studies the predictive risks increased after adjustment for IGFBP-3, and indeed in the Physicians' Health Study, lower normal range IGFBP-3 values predicted colorectal cancer (10) . A further study, using a cross-sectional design, has shown elevated levels of serum IGF-I and IGF-II in patients with colorectal cancer and argues that high circulating levels of IGF-II in addition to IGF-I,may be associated with increased cancer risk (11) . On the other hand, IGF-II and IGFBP-2 messenger ribonucleic acid (mRNA) expression and protein concentrations are elevated in colonic cancer cell lines (12) (13) (14) and in human colorectal adenocarcinomas (15) . One small uncontrolled study has demonstrated elevated serum levels of IGF-II and IGFBP-2 in patients diagnosed with colorectal carcinoma (16) .
These contrasting backgrounds led us to investigate the relationship between circulating IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma. The population chosen was a well defined age group of healthy individuals undergoing screening flexible sigmoidoscopy.
Subjects and Methods

Study design
We prospectively measured serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 in 345 individuals undergoing screening flexible sigmoidoscopy at 1 center (Christie Hospital NHS Trust) within a large multicenter randomized trial (Medical Research Council/Imperial Cancer Research Fund Flexi-Scope Trial) (17) . Volunteers were healthy individuals, aged 55-64 yr, with no previous colonic pathology and without a strong family history of colorectal cancer. Height and weight were measured, and body mass index (BMI) was calculated in all participants. In females, hormonal replacement therapy (HRT) usage within 3 months of endoscopic examination was recorded, as this may influence circulating IGF levels (18) . Excluded from the study were individuals with 1 or more of the following medical conditions that may alter serum IGF levels: history of diabetes mellitus, current treatment with psychotropic medication, or treatment for thyroid disease. The study was approved by the local ethics committee for South Manchester Health Authorities, and written informed consent was obtained from each participant.
Endoscopic and histological examination
All individuals had a screening flexible sigmoidoscopy performed without sedation by a single endoscopist (J.E.P.). Macroscopic evaluation was undertaken, reaching a median distance of 62 cm (range, 10 -90 cm), limited in the main by patient discomfort. All polyps were removed and/or biopsied endoscopically, examined histologically, and classified as nonneoplastic (predominantly hyperplastic) or neoplastic (adenomas). Adenomas were further classified as tubular, tubulovillous, or villous, and epithelial dysplasia was graded as mild, moderate, or severe in accordance with the WHO criteria (19) . Site was categorized as either rectum or left colon (sigmoid, descending colon, splenic flexure). All patients with high risk adenomas (adenoma size Ն1 cm, tubulovillous/ villous histology, severe dysplasia, more than two adenomas) as defined by Atkin et al. (20) , underwent subsequent colonoscopy to examine the remainder of the large bowel, but only endoscopic findings at the first pass examination (i.e. flexible sigmoidoscopy) are included in this analysis. Individuals with a macroscopic normal rectum and distal colon and those with hyperplastic polyps only were considered controls, as there is no evidence that these polyps have a malignant potential (21) .
Assays
A nonfasting blood sample was taken from all individuals before sigmoidoscopy, centrifuged after standing for 1 h, and stored at Ϫ80 C. Additional samples were obtained 10 -12 weeks after normal endoscopic examination in 20 individuals and after polypectomy in 31 individuals with adenomas. Serum was assayed blind to the status of adenoma or control. Masked samples were also included within each batch to determine variability; the interbatch coefficients of variation for IGF-I, IGF-II, IGFBP-2, and IGFBP-3 were 12%, 9%, 12%, and 5%, respectively.
IGF-I was measured, after acid-alcohol extraction, by a well established RIA using a polyclonal rabbit antiserum (R557A) raised against purified human IGF-I (22, 23) . Serum IGF-II was determined using a commercially available extraction immunoradiometric assay kit (Diagnostic Systems Laboratories, Inc., Webster, TX). IGF-II values using this assay show excellent agreement with determinants using acid chromatography, and cross-reactivity between IGF-I and IGF-II is less than 1% (24) . IGFBP-2 and IGFBP-3 were measured by RIA and immunoradiometric assay, respectively, with commercially available kits (Diagnostic Systems Laboratories, Inc.). All samples were assayed in triplicate; the interassay coefficients of variation at low, medium and high analyte levels were less than 10% for all four assays, with intraassay coefficients of variation less than 5%. The sensitivities for IGF-I, IGF-II, IGFBP-2, and IGFBP-3 were 14 ng/mL, 15 ng/L, 5 ng/mL, and 0.5 g/mL, respectively.
Immunohistochemistry
Immunohistochemical studies using a polyclonal antibody raised against human IGF-II peptide (Cambridge Biosciences, Cambridge, UK) were performed on 66 adenomas (from all 52 patients with adenomas), 10 hyperplastic polyps, and 10 normal colonic mucosal specimens. The hyperplastic polyp specimens and pinch biopsies of normal mucosa (left colon) were from individuals without adenomas in the same study cohort. Only well orientated sections of normal mucosa allowing assessment of at least 20 longitudinal whole crypts were included. An avidin-biotin method was used after overnight incubation at 4 C with the primary antibody (1:200) as previously described (25) . Positive (human cirrhotic liver) and negative (mouse IgG) controls were used, and IGF-II immunostaining was validated using dilutional and IGF-II peptide (1:10; Cambridge Biosciences, Cambridge, UK) blocking experiments.
Statistical analysis
The main end points were the relationships between circulating IGF-I and IGF-II, and the presence of adenomas. IGF-II, IGFBP-2, and IGFBP-3 determinants were normally distributed and accepting a mild degree of skewness in the IGF-I distribution (by one-sample Kolmogorov-Smirnov test, P ϭ 0.04), the data are presented as the mean Ϯ sd. Differences in means were compared using unpaired and paired Student's t tests, one-way ANOVA, and Duncan's multiple range tests as appropriate. The probability of an individual having an adenoma was assessed using logistic regression models, and comparisons were made with likelihood ratio tests. The candidate predictors considered were IGF-I, IGF-II, IGFBP-2, IGFBP-3, BMI (all as continuous variables), and sex, including HRT status in females (as a categorical variable). Correlations were expressed as Pearson's coefficient (r). P Ͻ 0.05 was considered to indicate statistical significance. SPSS 7.0 (SPSS, Inc., Chicago, IL) and SPlus (MathSoft, Seattle, WA) computer software were used for computations.
Results
Associations of IGFs and binding proteins
Across the narrow age band studied (10 yr), there were no significant changes in serum IGF-I, IGF-II, IGFBP-2, or IGFBP-3 with age. Serum IGFBP-3 was positively associated with both IGF-I (r ϭ 0.59; P Ͻ 0.001) and IGF-II (r ϭ 0.58; P Ͻ 0.001). By contrast, IGFBP-2 was negatively related to IGF-I (r ϭ Ϫ0.21; P Ͻ 0.001) and IGF-II (r ϭ Ϫ0.22; P Ͻ 0.001). Standardized residual plots for the ligands vs. the binding proteins were linear for the full range of values, suggesting that there was no significant interference by high levels of binding protein in the preassay extraction processes.
Adenomas vs. controls
Of the 345 participants, at least 1 adenoma was diagnosed in 52 individuals (15%). There was no difference in the incidence of adenomas between males (17%) and females (13%), although in females, adenomas were more frequent in those receiving HRT. There were no differences in age, height, body weight, or body mass index between controls and individuals with adenomas for either sex ( Table 1) .
The most striking finding was an elevated mean serum IGF-II in screened individuals with adenomas compared with controls (mean difference, 139 ng/mL; 95% confidence interval, 82, 196; by unpaired Student's t test, P Ͻ 0.0001). This significant association remained true for both sexes and including HRT status in females (Table 2 ). In addition, the (IGF-I plus IGF-II)/IGFBP-3 molar ratio was significantly elevated in individuals with adenoma (mean difference, 0.15; 95% confidence interval, 0.09, 0.21; P Ͻ 0.001). Logistic regression adjusting for sex, HRT status, BMI, IGF-I, and the binding proteins confirmed the significant association between IGF-II and adenoma occurrence (P Ͻ 0.0001). By univariate analysis, serum IGFBP-2 was not associated with the presence of adenomas, but the logistic regression model, adjusting for the above factors, including IGF-II, revealed a significant positive association with adenomas (P ϭ 0.0001; Table 3 ). The odds ratios for the presence of an adenoma per sd change in IGF-II and IGFBP-2 concentrations were 3.05 and 2.26, respectively.
For serum IGF-I, there was no statistical difference in mean values in individuals with adenomas compared with control values. Similarly, there were no differences in mean IGFBP-3 levels between adenoma and control individuals ( Table 2) . Separate logistic regression models were explored for the predictive values of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio (similar to analyses in Refs. 9 -11), but none yielded a significant association with the presence of adenomas.
We explored the relationship between serum IGF-II and serum IGFBP-2 values and adenoma characteristics (Table 4) . Serum IGF-II levels were elevated in all adenoma subgroups compared with controls (all P Ͻ 0.001), but there were no significant differences between individual subgroups. Serum IGFBP-2 was raised in individuals with large adenomas, almost reaching statistical significance compared with controls (P ϭ 0.06).
Repeat samples
We also analyzed serum IGF-II and IGFBP-2 values in 31 individuals pre-and postpolypectomy. There were significant falls in both IGF-II (by paired Student's t test, P Ͻ 0.001) and IGFBP-2 (P Ͻ 0.001) levels postpolypectomy, with a return toward the normal range determined from the controls (Fig. 1, A and C) . In 20 individuals without adenomas, there were no differences in IGF-II or IGFBP-2 values between repeated samples taken 2 months apart (Fig. 1, B and D).
Immunohistochemical expression
The immunostaining studies showed no IGF-II peptide expression in normal colonic epithelium (Fig. 2) or hyperplastic polyps (not shown). In contrast, IGF-II expression was observed on the apical perinuclear side of the epithelial cells in 55 of 66 (83%) adenomas. IGF-II positivity was 89%, 72%, and 100% for adenomas less than 0.5 cm, 0.5-1.0 cm, and greater than 1.0 cm in size, respectively.
Tumor marker characteristics
The results of the repeat sample studies and immunostaining studies led us to explore the potential tumor marker characteristics of IGF-II and/or IGFBP-2. We searched for ideal screening characteristics using a receiver operator characteristic (ROC) curve (26), but no ideal cutpoints (high sensitivity, high specificity) for IGF-II alone were forthcoming. When IGF-II was combined with IGFBP-2 in a hypothetical distribution generated from the logistic regression model, the most favorable cutpoint was found in the lower third of the distribution at which the negative predictive value was 0.97, the positive predictive value was 0.19, the sensitivity was 0.94, and the specificity was 0.31.
Discussion
This is the first study that has investigated the relationship among both IGFs, their binding proteins, and the presence of colorectal adenomas (in a nonacromegalic population). IGFs are markedly influenced by age (1) , and accordingly, the setting of a screening trial in an age-defined group of healthy individuals afforded us a unique opportunity to compare index cases with true controls. The key finding was a positive association between circulating IGF-II and the presence of adenomas, detected by flexible sigmoidoscopy. This observation was supported by the results of our multivariate analysis, which also revealed a significant association between IGFBP-2 and adenomas. Significant reductions in both serum IGF-II and IGFBP-2 levels were demonstrated after adenoma removal, and together with IGF-II immunoexpression in a high proportion of adenomas suggests a novel tumor marker in individuals with adenomas. The lack of association between IGF-I and/or IGFBP-3 and the presence of adenomas represents an important negative finding in this study.
Our immunostaining studies are consistent with the observations that background expression of IGF-II in normal colonic epithelium is absent or minimal (12) . In contrast, IGF-II positivity was demonstrated in 83% of all our adenomas, and we postulate that the elevations in circulating IGF-II reflect direct adenoma production. In support of this, mutations of the IGF-II gene are among the most frequently seen in colorectal cancers (27) , and IGF-II mRNA and peptide are overexpressed in human colorectal adenocarcinomas (15) . An alternative, although partial, explanation may be loss of imprinting (LOI) in IGF-II gene in adjacent normal mucosa of individuals harboring adenomas. LOI is believed to contribute to IGF-II overexpression in tumors (28) , and Cui and colleagues (29) observed LOI of the IGF-II gene in colorectal cancers and paired histological normal mucosa, but not in normal mucosa from noncancer patients. This hypothesis is attractive, but fails to explain the observed fall in serum IGF-II levels after polypectomy in our patients and requires further study.
Elevated serum IGF-II levels have been reported in a study with a small number of patients with colorectal cancer (16) . In addition, researchers have reported case series in which increased amounts of big or pro-IGF-II are observed in patients with malignancy, typically uncommon sarcomas (30) . Pro-IGF-II is incompletely sequestered in high mol wt IGFBP-3 complexes and therefore is capable of exerting potent insulin-like activity causing nonislet cell tumor-associated hypoglycemia. In this setting, normal IGF-II levels are decreased (31) . Elevated pro-IGF-II levels are not detected in patients with colorectal cancer (16) , and clearly, hypoglycemia was not a significant clinical problem in our patients with adenomas. We believe that in individuals with adenomas, there is a true increase in the amount of normal IGF-II in the serum [as reflected by the increase in the (IGF-I plus IGF-II)/IGFBP-3 molar ratio], most of which is sequestered by IGFBP-3 and IGFBP-2 (which is normally unsaturated), thereby preventing it from exerting an insulin-like effect.
This study has also shown an association between IGFBP-2 and the presence of adenomas. Serum IGFBP-2 levels are elevated in patients with colorectal cancer (16) , and, notably a Individuals with more than one adenoma were designated to an adenoma subgroup determined by the adenoma with the greater hierarchical characteristic in that individual.
b Differences in means between adenoma subgroups and controls compared by one-way ANOVA.
c Differences between adenoma subgroups compared using Duncan's multiple range test.
in our study, levels were raised in individuals with large adenomas. IGFBP-2 mRNA expression is increased in colonic adenocarcinomas and other cancers (32) , and increased serum levels originating directly from tumor cells have been demonstrated in childhood leukemia (33) .
We failed to demonstrate an association between IGF-I, IGFBP-3, or IGF-I/IGFBP-3 ratio and the presence of adenoma. At first glance, this appears to be at variance with the Physicians' Health Study (11) , but it may reflect the numbers and types of adenomas in this cohort. In a parallel study in individuals undergoing screening colonoscopy to the cecum and with larger numbers of individuals with high risk ad- enomas, we found that serum IGF-I is positively and IGFBP-3 is independently inversely associated with the presence of high risk adenoma, but not low risk adenomas (34) . Similarly, circulating IGF-I has been implicated as a contributing factor to the putative increased risk of colonic neoplasia in acromegaly. In our acromegalic series, we failed to show either an increased prevalence of adenomas compared with controls or a correlation of colorectal neoplasia with serum IGF-I (35). However, where adenomas occurred, they tend to be large in size with advanced histology (35, 36) , and it is tempting to suggest that serum IGF-I may predict the progression of small inconsequential adenomas to high risk lesions. We also found an association (in the multivariate analysis) between BMI and the presence of adenomas, consistent with evidence linking obesity to the frequency of adenomas (37) . In contrast to recent reports suggesting that HRT is protective for colorectal adenomas (38), we found a positive association in our cohort. This is an area that requires large studies to draw more definitive conclusions, as there are many issues, such as duration of use, type of HRT, and current user status, that need to be considered (39) .
The association between serum IGF-II and adenomas demonstrated in this study points to a novel tumor marker for a premalignant lesion. Large studies have shown that the detection and removal of adenomatous polyps results in dramatic reductions (70 -90%) in the subsequent development of colorectal cancer (40) . From our data, the characteristics of IGF-II as a screening tool were not ideal, but the falls in both IGF-II and IGFBP-2 after adenoma removal were most striking. Importantly, serum IGF-II and IGFBP-2 levels in individuals without adenomas remained stable with time. These results provide the stimulus to study further the place of these endocrine markers in adenoma surveillance. It is conceivable that careful and regular monitoring of postpolypectomy IGF-II and IGFBP-2 levels in patients with known adenomas may dictate when and who undergoes repeat colonoscopy.
In conclusion, this study has shown a positive association between serum IGF-II and adjusted IGFBP-2, and the presence of adenomas and has suggested for the first time that serum IGF-II may be a potential tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy.
